[Effect of different frequencies electroacupuncture at "Zusanli"(ST36) on visceral sensitivity and adrenocorticotropin releasing factor expression in IBS mice].

Researchers investigated whether electroacupuncture at the Zusanli (ST36) acupuncture point could help irritable bowel syndrome (IBS) in mice, and whether different electrical frequencies would produce different results. IBS causes abdominal pain, changes in bowel habits, and often accompanies anxiety and depression. The study compared three electrical frequencies: low (2 Hz), medium (15 Hz), and alternating (2 Hz/15 Hz) stimulation applied for 15 minutes daily over seven days. Mice with IBS showed heightened gut sensitivity, anxiety-like behaviors, intestinal inflammation, and elevated stress hormones in both the gut and brain. All three electroacupuncture treatments improved these symptoms, reducing gut sensitivity, decreasing anxiety behaviors, and lowering inflammation. The treatments worked by reducing the number of specialized immune cells (mast cells) in the colon and normalizing stress hormone signaling pathways between the brain and gut. The alternating frequency (2 Hz/15 Hz) proved most effective, outperforming single-frequency treatments in reducing gut hypersensitivity, improving emotional state, and normalizing stress hormone levels. This suggests that electroacupuncture may help IBS by calming the brain-gut communication pathway that becomes overactive during stress. While this animal study shows promise, human research is needed to confirm these effects. If you're considering acupuncture for IBS symptoms, consult with a licensed acupuncturist who has experience treating digestive disorders.

This study examined frequency-specific electroacupuncture effects on IBS in mice (n=9 per group) using chronic unpredictable stress modeling. Bilateral ST36 received 1 mA stimulation at 2 Hz, 15 Hz, or alternating 2 Hz/15 Hz for 15 minutes daily over seven days. All EA protocols reduced abdominal withdrawal reflex scores, improved open field test performance, and decreased colonic mast cell counts and inflammatory infiltration. Mechanistically, EA downregulated CRF, CRFR1, and CRFR2 protein expression in colon tissue, decreased hypothalamic CRF and CRFR1, while upregulating hypothalamic CRFR2. The alternating frequency protocol demonstrated superior outcomes across visceral sensitivity, mast cell regulation, and CRF pathway modulation compared to single-frequency treatments (P<0.05). Clinical implications suggest dense-dispersed EA may optimize gut-brain axis regulation in IBS through dual modulation of peripheral colonic and central hypothalamic CRF signaling pathways.